Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) from a strong-buy rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Several other equities research analysts have also issued reports on the company. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, September 25th. B. Riley set a $8.00 price target on Rexahn Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 13th. Finally, Ifs Securities raised Rexahn Pharmaceuticals from an outperform rating to a strong-buy rating in a research report on Thursday, October 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $9.92.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its quarterly earnings results on Monday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Northern Trust Corp boosted its stake in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,213 shares of the company’s stock after buying an additional 29,354 shares during the period. Northern Trust Corp owned 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent SEC filing.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Recommended Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.